Skip to main content
Erschienen in: Clinical Rheumatology 6/2017

05.05.2017 | Original Article

MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance

verfasst von: Aurélie Chausset, Tiphaine Fargeix, Bruno Pereira, Stéphane Echaubard, Agnès Duquesne, Marine Desjonquères, Caroline Freychet, Alexandre Belot, Etienne Merlin

Erschienen in: Clinical Rheumatology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to assess the relevance for children and parents to use the French-validated version of the methotrexate intolerance severity score (MISS), a measure of methotrexate intolerance for children suffering from juvenile idiopathic arthritis. The French-version MISS was developed following the “Guidelines for the process of cross-cultural adaptation of self-report measures.” The new version was tested in families of children with juvenile idiopathic arthritis who completed the questionnaire twice at a 2-week interval. Item correlations, Cronbach’s alpha, and kappa coefficients were computed to evaluate acceptability, internal consistency, and reproducibility. A culturally acceptable version to French was obtained. A total of 71 individuals were included from May 2015 to November 2015. The results show very good acceptability: good response rate (80%), few missing data (<1%) and good understanding of parents and children. The inter-item, dimension-item, and inter-dimension correlations were satisfactory (except for “vomiting” items–other items correlation). Cronbach’s alpha coefficient was well higher than the usually recommended value of 0.6. The results of validity of internal and external consistencies were satisfactory. We also found good agreement between the test-retest for every family. The empirical discriminative cut-off point of 3 showed a sensitivity of 86% and a specificity of 83%. The MISS questionnaire is quick to complete, easy to use. It can be completed by children or their parents with no significant difference. This validated French-version MISS can help study prevalence and risk factors of methotrexate intolerance, better detect this intolerance, and provide better support for patients on long-term treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Murray KJ, Lovell DJ (2002) Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 16:361–378CrossRefPubMed Murray KJ, Lovell DJ (2002) Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 16:361–378CrossRefPubMed
3.
Zurück zum Zitat Ortiz-Alvarez O, Morishita K, Avery G et al (2004) Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 31:2501–2506PubMed Ortiz-Alvarez O, Morishita K, Avery G et al (2004) Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 31:2501–2506PubMed
4.
Zurück zum Zitat Niehues T, Horneff G, Michels H et al (2005) Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 25:169–178. doi:10.1007/s00296-004-0537-y CrossRefPubMed Niehues T, Horneff G, Michels H et al (2005) Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 25:169–178. doi:10.​1007/​s00296-004-0537-y CrossRefPubMed
5.
Zurück zum Zitat Brunner HIM, Johnson ALB, Barron AC et al (2005) Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol 11:194–204CrossRefPubMed Brunner HIM, Johnson ALB, Barron AC et al (2005) Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol 11:194–204CrossRefPubMed
6.
Zurück zum Zitat van der Meer A, Wulffraat NM, Prakken BJ et al (2007) Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 25:480–485PubMed van der Meer A, Wulffraat NM, Prakken BJ et al (2007) Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 25:480–485PubMed
7.
Zurück zum Zitat Mulligan K, Kassoumeri L, Etheridge A et al (2013) Mothers’ reports of the difficulties that their children experience in taking methotrexate for juvenile idiopathic arthritis and how these impact on quality of life. Pediatr Rheumatol Online J 11:23. doi:10.1186/1546-0096-11-23 CrossRefPubMedPubMedCentral Mulligan K, Kassoumeri L, Etheridge A et al (2013) Mothers’ reports of the difficulties that their children experience in taking methotrexate for juvenile idiopathic arthritis and how these impact on quality of life. Pediatr Rheumatol Online J 11:23. doi:10.​1186/​1546-0096-11-23 CrossRefPubMedPubMedCentral
8.
10.
Zurück zum Zitat Ravelli A, Migliavacca D, Viola S et al (1999) Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17:625–627PubMed Ravelli A, Migliavacca D, Viola S et al (1999) Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17:625–627PubMed
11.
12.
Zurück zum Zitat Bulatović M, Heijstek MW, Verkaaik M et al (2011) High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 63:2007–2013. doi:10.1002/art.30367 CrossRefPubMed Bulatović M, Heijstek MW, Verkaaik M et al (2011) High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 63:2007–2013. doi:10.​1002/​art.​30367 CrossRefPubMed
13.
Zurück zum Zitat Ćalasan MB, van den Bosch OF, Creemers MC et al (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15:R217. doi:10.1186/ar4413 CrossRefPubMed Ćalasan MB, van den Bosch OF, Creemers MC et al (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15:R217. doi:10.​1186/​ar4413 CrossRefPubMed
15.
Zurück zum Zitat van Dijkhuizen EH, Ćalasan MB, Pluijm SM et al (2015) Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol 13:5. doi:10.1186/s12969-015-0002-3 CrossRef van Dijkhuizen EH, Ćalasan MB, Pluijm SM et al (2015) Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol 13:5. doi:10.​1186/​s12969-015-0002-3 CrossRef
16.
Zurück zum Zitat Beaton DE, Bombardier C, Guillemin F, Ferraz MB (2000) Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25:3186–3191CrossRefPubMed Beaton DE, Bombardier C, Guillemin F, Ferraz MB (2000) Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25:3186–3191CrossRefPubMed
18.
Zurück zum Zitat Wild D, Grove A, Martin M et al (2005) Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8:94–104. doi:10.1111/j.1524-4733.2005.04054.x CrossRefPubMed Wild D, Grove A, Martin M et al (2005) Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8:94–104. doi:10.​1111/​j.​1524-4733.​2005.​04054.​x CrossRefPubMed
19.
Zurück zum Zitat Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
21.
Zurück zum Zitat Fitzpatrick R, Davey C, Buxton MJ, Jones DR (1998) Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess Winch Engl 2(i–iv):1–74 Fitzpatrick R, Davey C, Buxton MJ, Jones DR (1998) Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess Winch Engl 2(i–iv):1–74
22.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
23.
Zurück zum Zitat Fatimah N, Salim B, Nasim A et al (2016) Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol 35:1341–1345. doi:10.1007/s10067-016-3243-8 CrossRefPubMed Fatimah N, Salim B, Nasim A et al (2016) Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol 35:1341–1345. doi:10.​1007/​s10067-016-3243-8 CrossRefPubMed
27.
Zurück zum Zitat Russell KMW, Hudson M, Long A, Phipps S (2006) Assessment of health-related quality of life in children with cancer: consistency and agreement between parent and child reports. Cancer 106:2267–2274. doi:10.1002/cncr.21871 CrossRefPubMed Russell KMW, Hudson M, Long A, Phipps S (2006) Assessment of health-related quality of life in children with cancer: consistency and agreement between parent and child reports. Cancer 106:2267–2274. doi:10.​1002/​cncr.​21871 CrossRefPubMed
28.
Zurück zum Zitat Sawyer MG, Carbone JA, Whitham JN et al (2005) The relationship between health-related quality of life, pain, and coping strategies in juvenile arthritis—a one year prospective study. Qual Life Res 14:1585–1598. doi:10.1007/s11136-004-7710-3 CrossRefPubMed Sawyer MG, Carbone JA, Whitham JN et al (2005) The relationship between health-related quality of life, pain, and coping strategies in juvenile arthritis—a one year prospective study. Qual Life Res 14:1585–1598. doi:10.​1007/​s11136-004-7710-3 CrossRefPubMed
30.
Zurück zum Zitat Dolgin MJ, Katz ER, McGinty K, Siegel SE (1985) Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 75:547–552PubMed Dolgin MJ, Katz ER, McGinty K, Siegel SE (1985) Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 75:547–552PubMed
31.
Zurück zum Zitat Myers MG, Cairns JA, Singer J (1987) The consent form as a possible cause of side effects. Clin Pharmacol Ther 42:250–253CrossRefPubMed Myers MG, Cairns JA, Singer J (1987) The consent form as a possible cause of side effects. Clin Pharmacol Ther 42:250–253CrossRefPubMed
Metadaten
Titel
MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance
verfasst von
Aurélie Chausset
Tiphaine Fargeix
Bruno Pereira
Stéphane Echaubard
Agnès Duquesne
Marine Desjonquères
Caroline Freychet
Alexandre Belot
Etienne Merlin
Publikationsdatum
05.05.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 6/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3638-1

Weitere Artikel der Ausgabe 6/2017

Clinical Rheumatology 6/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.